ofatumumab
Showing 1 - 25 of 81
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Tampa (High Dose Methylprednisolone (HDMP), Ofatumumab,
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- High Dose Methylprednisolone (HDMP)
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jan 12, 2023
Leukemia, Lymphoma Trial in Houston (Ofatumumab)
Active, not recruiting
- Leukemia
- Lymphoma
- Ofatumumab
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 9, 2022
Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia) Trial run by the National Heart, Lung, and Blood Institute
Active, not recruiting
- Small Lymphocytic Lymphoma
- CLL (Chronic Lymphocytic Leukemia)
- Fludarabine Phosphate
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 13, 2022
Ocrelizumab and Ofatumumab Administration in Relapsing Multiple
Completed
- Relapsing Forms of Multiple Sclerosis
- Ocrelizumab
- Ofatumumab
-
Lutherville, Maryland
- +1 more
Oct 19, 2022
Multiple Sclerosis Trial in Germany (Ofatumumab)
Active, not recruiting
- Multiple Sclerosis
- Ofatumumab
-
Berlin, Germany
- +5 more
Jan 13, 2023
Neuromyelitis Optica Spectrum Disorder Trial in Xi'an (Ofatumumab)
Recruiting
- Neuromyelitis Optica Spectrum Disorder
- Ofatumumab
-
Xi'an, Shaanxi, ChinaTangdu Hospital
Aug 16, 2022
Chronic GVHD Trial in United States (Ofatumumab)
Completed
- Chronic Graft Versus Host Disease
- Ofatumumab
-
Phoenix, Arizona
- +3 more
Sep 30, 2022
Immune Cells and Meningeal Lymphatic Drainage in Demyelinating
Recruiting
- Multiple Sclerosis
- +2 more
- Ofatumumab
-
Tianjin, Tianjin, ChinaTianjin Medical University General Hospital
Oct 19, 2022
Relapsing Multiple Sclerosis (RMS) Trial in United States (Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate)
Recruiting
- Relapsing Multiple Sclerosis (RMS)
- Ofatumumab
- +2 more
-
Phoenix, Arizona
- +3 more
Jul 20, 2022
Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)
Completed
- Non-Hodgkin's Lymphoma
- Bendamustine
- +6 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Sep 14, 2022
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab
Recruiting
- Relapsing Remitting Multiple Sclerosis
- Ofatumumab
-
Los Angeles, CaliforniaUniversity of Southern California
Feb 3, 2022
Relapsing Multiple Sclerosis Trial in Japan, Russian Federation (Ofatumumab, Matching of ofatumumab)
Completed
- Relapsing Multiple Sclerosis
- Ofatumumab
- Matching placebo of ofatumumab
-
Toon-city, Ehime, Japan
- +13 more
Apr 27, 2022
Chronic Lymphocytic Leukemia Trial in Houston (Ofatumumab)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Ofatumumab
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 23, 2022
Relapse Remitting Multiple Sclerosis Trial in United States (Ofatumumab)
Recruiting
- Relapse Remitting Multiple Sclerosis
- Ofatumumab
-
Chandler, Arizona
- +16 more
Jan 13, 2023
Chronic Lymphocytic Leukemia Trial in Spain (Ofatumumab)
Completed
- Chronic Lymphocytic Leukemia
- Ofatumumab
-
Badalona, Spain
- +8 more
May 2, 2022
Diffuse Large Cell Lymphoma Relapsed/Refractory Trial in San Francisco (Ofatumumab, Etoposide, Cytarabine)
Completed
- Diffuse Large Cell Lymphoma Relapsed/Refractory
- Ofatumumab
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jun 5, 2022
Relapsing Multiple Sclerosis Trial in Puerto Rico, United States (Ofatumumab)
Recruiting
- Relapsing Multiple Sclerosis
- Ofatumumab
-
Birmingham, Alabama
- +16 more
Mar 22, 2022
Relapsing Multiple Sclerosis Trial in United States (Quadrivalent influenza vaccine, Ofatumumab)
Recruiting
- Relapsing Multiple Sclerosis
- Quadrivalent influenza vaccine
- Ofatumumab
-
Phoenix, Arizona
- +3 more
Aug 30, 2021
Relapsing Multiple Sclerosis Trial in Boston (Ofatumumab, [F-18]PBR06)
Recruiting
- Relapsing Multiple Sclerosis
- Ofatumumab
- [F-18]PBR06
-
Boston, MassachusettsPartners MS Center, 60 Fenwood Road
Jul 20, 2021
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Tampa (High Dose Methylprednisolone (HDMP), Ofatumumab,
Completed
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- High Dose Methylprednisolone (HDMP)
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Apr 2, 2021
Diffuse Large B Cell Lymphoma Trial in Poland (Ofatumumab, Etoposide, Ifosfamid)
Completed
- Diffuse Large B Cell Lymphoma
- Ofatumumab
- +7 more
-
Wrocław, Dolnośląskie, Poland
- +7 more
Dec 23, 2021
Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma Trial in
Active, not recruiting
- Stage I Mantle Cell Lymphoma
- +4 more
- Autologous Hematopoietic Stem Cell Transplantation
- +8 more
-
Buffalo, New York
- +1 more
Mar 9, 2022